Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double‐blind, placebo‐controlled clinical trial

AIMS: Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control. This Phase 1 clinical trial assessed the safety and tolerability, pharmacokinetics and preliminary efficacy of a novel MetAP2 inhibitor, ZGN‐1061. METHODS: This cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Malloy, Jaret, Zhuang, Dongliang, Kim, Terri, Inskeep, Phil, Kim, Dennis, Taylor, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055687/
https://www.ncbi.nlm.nih.gov/pubmed/29577550
http://dx.doi.org/10.1111/dom.13305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055687/
https://www.ncbi.nlm.nih.gov/pubmed/29577550
http://dx.doi.org/10.1111/dom.13305

Ejemplares similares